|Dr. Ali Tehrani||Co-Founder, Pres, CEO & Director||877.66k||N/A||1972|
|Mr. Neil A. Klompas C.A., CPA, CPA, CA||Exec. VP of Bus. Operations & CFO||589.86k||N/A||1972|
|Dr. Anthony J. Polverino||Chief Scientific Officer & Exec. VP of Early Devel.||606.71k||N/A||1963|
|Ms. Kathryn O'Driscoll||Chief People Officer||497.22k||N/A||1964|
|Dr. Diana F. Hausman||Exec. Advisor||636.61k||N/A||1963|
|Mr. Daniel Dex||VP of Legal & Corp. Sec.||N/A||N/A||N/A|
|Dr. Neil Josephson M.D.||Interim Chief Medical Officer & Sr. VP of Clinical Research||N/A||N/A||N/A|
|Mr. James Daniel Guylain Priour||Chief Commercial Officer||N/A||N/A||1967|
|Dr. David Poon Ph.D.||VP of Bus. Devel. and Alliance Management||N/A||N/A||N/A|
|Dr. Jennifer Kaufman-Shaw L.L.B., Ph.D., LLB||VP of Intellectual Property||N/A||N/A||1950|
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Zymeworks Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.